bit.bio secures $50 million Series C to scale human cell programming technology
Advertisement
bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding round led by M&G investments. This injection of patient capital from a major UK investor represents a significant endorsement of the company's mission to transform the future of drug development and innovation within the United Kingdom.
This capital infusion allows bit.bio to move toward several key strategic milestones, including accelerating the development and delivery of our core product pipeline while scaling our operational footprint to meet global demand. The company is expanding into the multi-billion dollar toxicology market and generating the high-fidelity datasets necessary to train advanced AI models for drug discovery.
Central to this effort is bit.bio's ioCells™ technology, which facilitates a global shift toward New Approach Methodologies (NAMs), in particular, advanced cell-based models that improve the predictiveness of new medicines while reducing industry reliance on animal testing.
Alongside this funding, bit.bio is pleased to welcome Lord David Prior to our leadership team as an independent director and Board Chair. Lord Prior’s twenty-year tenure in UK Life Sciences and health policy will be vital as we navigate our growth from a private entity toward public markets.
Przemek Obloj, CEO of bit.bio, commented: "By providing reliable human cells for research and safety testing, we’re helping to accelerate drug development and build a world class life sciences business in the UK. Our technology reduces reliance on animal testing while improving the relevance and accuracy of pre-clinical research. With fresh backing from M&G and our wider investor base, we can accelerate development, from in silico model training through our most established in vitro discovery models and towards safety testing."
Cornel Chiriac, Investment Director of Crossover, M&G Investments, said: “The investment of patient capital into a fast-growing private UK company, spun out from the University of Cambridge, marks a major vote of confidence in innovation and the future of drug development in the UK. bit.bio’s platform makes cell programming reliable, scalable, and commercially ready in a rapidly evolving field. As a long-term investor, M&G is committed to backing the next generation of UK businesses and driving economic progress. With a growing global footprint, bit.bio is a UK success story poised for international growth.”
Lord David Prior concluded: “bit.bio’s technology is world class and the opportunity is now converting that advantage into sustained commercial performance. I look forward to supporting the team as it expands its customer reach and becomes a key partner for pharmaceutical, biotech and research organisations worldwide.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.